Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology, Inc. director Victor Edward Tong Jr. received a grant of stock options covering 9,354 shares of common stock. The options have an exercise price of $56.09 per share and expire on June 3, 2036.
These options vest in 12 equal monthly installments after June 4, 2026, the grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion vests on the meeting date, contingent on his continued service.
CG Oncology, Inc. director James Mulay received a grant of stock options covering 9,354 shares of common stock. These options have an exercise price of $56.09 per share and expire on June 3, 2036.
Following this grant, Mulay holds options for 9,354 shares directly. According to the vesting terms, 1/12 of the options vest monthly after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs before the first anniversary, subject to his continuous service.
CG Oncology director Christina Rossi received a stock option grant covering 9,354 shares of common stock. The option has an exercise price of $56.09 per share and expires on June 3, 2036. Vesting occurs in 12 equal monthly installments after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within the first year, subject to her continued service.
CG Oncology, Inc. director Leonard E. Post reported an exercise-and-sale transaction plus a new option grant. He exercised 1,000 stock options at $0.60 per share and sold 1,000 common shares at $54.50 per share under a pre-arranged Rule 10b5-1 trading plan. He also received a fully vested grant of 9,354 director stock options with a $56.09 exercise price, while another option grant for 9,354 shares vests monthly after June 4, 2026. Following these transactions, he holds 1,000 common shares and 116,077 director stock options.
CG Oncology director Susan E. Graf received a grant of stock options covering 9,354 shares of common stock. The options have an exercise price of $56.09 per share and expire on June 3, 2036. They vest in 12 equal monthly installments beginning after June 4, 2026, subject to her continuous service, with any remaining unvested portion vesting at the next annual stockholder meeting if that occurs within a year. Following this grant, she holds 9,354 director stock options directly.
CG Oncology, Inc. announced that President & Chief Operating Officer Ambaw Bellete will separate from the company effective June 30, 2026, following an agreement reached on May 20, 2026. He is expected to receive severance benefits consistent with Section 4(b) of his 2025 employment agreement.
The company has begun a search for a Chief Commercial Officer and the board has appointed Arthur Kuan as President in addition to his existing roles. His background is described in CG Oncology’s definitive proxy statement filed on April 24, 2026.
CG Oncology Inc disclosure: T. Rowe Price Investment Management, Inc. reports 6,720,389 shares of Common Stock, representing 8.0% of the class as of 03/31/2026. The filing lists 6,459,822 shares of sole voting power and affirms that the filer denies beneficial ownership in the filing's declaration. The signature block is dated 05/15/2026.
CG Oncology, Inc. Schedule 13G discloses that RTW Investments, LP and Roderick Wong report shared beneficial ownership of 6,984,808 shares of Common Stock, representing 8.3% of the class based on 84,435,200 shares outstanding as of February 25, 2026.
The filing states the RTW Funds have the right to receive dividends or sale proceeds on these shares. The Reporting Persons report no sole voting or dispositive power; all voting and dispositive power is shared.
CG Oncology, Inc. reported a larger net loss as it invests heavily in late-stage bladder cancer programs while strengthening its balance sheet. For the three months ended March 31, 2026, total revenue was $1.1 million, including $1.1 million of commercial and development revenue from Biovire and a small amount of license revenue. Operating expenses rose to $67.5 million, driven by $43.7 million in research and development and $20.8 million in general and administrative costs, leading to a net loss of $60.2 million versus $34.5 million a year earlier.
The company ended March 31, 2026 with $1,076.2 million in cash, cash equivalents and marketable securities, supported by $391.4 million of net proceeds from an at-the-market offering during the quarter. As of that date, accumulated deficit was $439.2 million and 88,007,761 common shares were outstanding. Management believes existing funds can support operations for at least twelve months while it advances its Biologics License Application for cretostimogene grenadenorepvec in non-muscle invasive bladder cancer.